ストックスクリーナーアプリを入手
7.67
2.54%
-0.20
アフターアワーズ：
7.60
-0.07
-0.91%
前日終値:
$7.87
開ける：
$7.96
24時間の取引高:
310.02K
Relative Volume:
0.83
時価総額：
$372.67M
収益：
$251.00K
当期純損益:
$-83.87M
株価収益率:
-2.2356
EPS:
-3.4309
ネットキャッシュフロー:
$-79.34M
1週間 パフォーマンス:
-10.29%
1か月 パフォーマンス:
-25.68%
6か月 パフォーマンス:
+114.25%
1年 パフォーマンス:
+293.33%
1日の値動き範囲:
$7.60
$8.18
1週間の範囲:
$7.60
$9.045
52週間の値動き範囲:
$1.47
$14.53
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
名前
Artiva Biotherapeutics Inc
セクター
電話
(858) 267-4467
住所
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
7.67 | 382.39M | 251.00K | -83.87M | -79.34M | -3.4309 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 再開されました | H.C. Wainwright | Buy |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 開始されました | Jefferies | Buy |
| 2024-08-13 | 開始されました | Needham | Buy |
| 2024-08-13 | 開始されました | TD Cowen | Buy |
| 2024-08-13 | 開始されました | Wedbush | Outperform |
すべてを表示
Artiva Biotherapeutics Inc (ARTV) 最新ニュース
Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating By Investing.com - Investing.com Australia
ARTV Stock Price, Quote & Chart | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock By Investing.com - Investing.com Nigeria
As Griffith retires, Dittrich returns to Amgen, takes CFO role - biocentury.com
Artiva Biotherapeutics COO Jennifer Bush sells $79,178 in stock By Investing.com - Investing.com Nigeria
Artiva names Diego Miralles as president and head of R&D - The Pharma Letter
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock - Investing.com India
Artiva Biotherapeutics COO Jennifer Bush sells $79,178 in stock - Investing.com India
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock - Investing.com India
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock By Investing.com - Investing.com Australia
Artiva Biotherapeutics officer Christopher Horan sells $63,072 in stock - Investing.com India
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock - Investing.com India
Artiva Biotherapeutics officer Christopher Horan sells $63,072 in stock By Investing.com - Investing.com Australia
Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases - Traders Union
Artiva Biotherapeutics announces executive changes and new appointments By Investing.com - Investing.com Nigeria
Artiva to present AlloNK therapy data at EULAR congress - Investing.com India
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases - Yahoo Finance
Artiva Biotherapeutics appoints Diego Miralles as president, R&D head By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics, Inc. Appoints New Principal Financial Officer and President in May 2026 - Minichart
Artiva Biotherapeutics announces executive changes and new appointments - Investing.com
Artiva Biotherapeutics Inc Thad Huston to separate as CFO effective May 22, 2026 - marketscreener.com
Artiva Biotherapeutics Inc Thad Huston To Separate As CFO Effective May 22, 2026 - TradingView
Artiva Biotherapeutics Names Diego Miralles, M.D., as Pres and Head of Research and Development >ARTV - Moomoo
Artiva Biotherapeutics Announces Major Executive Leadership Transitions - TipRanks
Artiva Biotherapeutics appoints Diego Miralles as president, R&D head - Investing.com
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, ... - Enidnews.com
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development - Yahoo Finance UK
Artiva Biotherapeutics (ARTV) price target increased by 60.00% to 27.74 - MSN
Major Insider Move Signals Big Confidence in Artiva Biotherapeutics - TipRanks
Ra Capital Management acquires $75m in Artiva Biotherapeutics shares By Investing.com - Investing.com Australia
Ra Capital Management acquires $75m in Artiva Biotherapeutics shares - Investing.com
TradingKey - TradingKey
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Raises Target Price to $41 - Moomoo
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating - Moomoo
Business News, Finance News, Stock Market - RTTNews
Cantor Fitzgerald Boosts Artiva Biotherapeutics (NASDAQ:ARTV) Price Target to $40.00 - MarketBeat
H.C. Wainwright raises Artiva Biotherapeutics price target to $35 - Investing.com
H.C. Wainwright raises Artiva Biotherapeutics price target to $35 By Investing.com - Investing.com Canada
Artiva Biotherapeutics stock slides despite positive trial data - MSN
Number of shareholders of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV - TradingView
Artiva Biotherapeutics Announces $300 Million Equity Offering - The Globe and Mail
Artiva Biotherapeutics: Runway To Fund Operations Into 2Q 2027 >ARTV - Moomoo
Artiva Biotherapeutics Announces Underwriting Agreement and Public Offering of Shares and Pre-Funded Warrants - Minichart
Latham Watkins Advises on Artiva Biotherapeutics Offering of Common Stock and Pre Funded Warrants - Latham & Watkins LLP
Artiva reports clinical trial data for rheumatoid arthritis therapy - Investing.com UK
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA - Seeking Alpha
Artiva Biotherapeutics Inc (ARTV) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):